600216.SS SHH
Zhejiang Medicine Co., Ltd.
1W: -2.3%
1M: -3.9%
3M: +6.2%
YTD: -23.0%
1Y: -20.1%
3Y: +16.9%
5Y: -8.2%
¥12.43 ($1.85)
+0.25 (+2.05%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$1.2B
+92.9% ▲
5Y CAGR: +22.3%
Capital Expenditures
$689M
+13.5% ▲
5Y CAGR: +3.7%
Free Cash Flow
$534M
+428.6% ▲
Dividends Paid
$143M
+13.1% ▲
Buybacks
$29M
-2143.2% ▼
Net Change in Cash
$506M
+2206.1% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $660M | $885M | $363M | $277M | $1.0B |
| Depreciation & Amort. | $504M | $588M | $682M | $725M | $724M |
| Stock-Based Comp. | $1M | $42M | $33M | $0 | $0 |
| Change in Working Capital | -$6M | -$568M | -$727M | -$256M | -$801M |
| Other Non-Cash Items | $119M | $173M | $187M | -$112M | $281M |
| Operating Cash Flow | $1.3B | $1.1B | $521M | $634M | $1.2B |
| — Investing Activities — | |||||
| Capital Expenditures | -$535M | -$940M | -$976M | -$797M | -$689M |
| Acquisitions (Net) | $27M | -$141M | $9M | $0 | $0 |
| Investment Purchases | -$326M | -$282M | -$357M | -$209M | -$453M |
| Investment Sales | $454M | $321M | $440M | $193M | $428M |
| Other Investing | $142M | $58M | -$87M | $348M | $241M |
| Investing Cash Flow | -$238M | -$984M | -$971M | -$465M | -$473M |
| — Financing Activities — | |||||
| Net Debt Issuance | $302M | -$120M | -$65M | -$342K | -$53M |
| Stock Repurchased | $0 | $0 | $0 | -$1M | -$29M |
| Dividends Paid | -$1.0B | -$220M | -$318M | -$164M | -$143M |
| Other Financing | $22M | $410M | $460M | -$30M | -$31M |
| Financing Cash Flow | -$627M | $70M | $44M | -$195M | -$255M |
| Net Change in Cash | $349M | $143M | -$331M | $22M | $506M |
| Cash End of Period | $1.6B | $1.8B | $1.4B | $1.5B | $2.0B |
| Free Cash Flow | $721M | $197M | -$455M | -$163M | $534M |